Mechanism of action
Melanotan II is a non-selective agonist of the melanocortin receptor family. At MC1R on cutaneous melanocytes, receptor activation stimulates the cAMP/PKA cascade and the transcription factor MITF, upregulating tyrosinase and shifting pigment synthesis toward eumelanin, the mechanism underlying the tanning response observed in studies. Unlike the endogenous ligand α-MSH, the molecule is a conformationally constrained cyclic lactam heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2), which increases receptor potency and resistance to enzymatic degradation. Because it also activates MC3R and MC4R in the hypothalamus, systemic administration produces central effects: MC4R signalling is linked to reduced appetite and to the pro-erectile responses observed in early clinical studies. This lack of receptor selectivity explains its broad, partly unwanted pharmacology; the related α-MSH analog afamelanotide, by contrast, was developed specifically for MC1R-mediated photoprotection and taken through a formal clinical trial programme (Langan et al., 2010). Reliable published human data on the plasma half-life of Melanotan II are lacking; figures quoted in secondary literature range from under an hour to several hours.
State of evidence
Human data on Melanotan II are limited to small early-phase studies from the 1990s. A pilot phase I study at the University of Arizona (Dorr et al., 1996) reported increased skin pigmentation after repeated subcutaneous doses in a small number of healthy men, alongside nausea, somnolence and spontaneous erections. A double-blind, placebo-controlled crossover pilot in ten men with organic erectile dysfunction (Wessells et al., 2000) observed erectogenic responses. Clinical development was subsequently discontinued; the related compound bremelanotide (PT-141) was pursued instead (Hadley and Dorr, 2006). No phase 2 or phase 3 program was ever completed, and Melanotan II holds no regulatory approval as a medicine in any jurisdiction. Products circulating since then are unregulated, and the dermatological literature describes adverse events in users of unlicensed material, including rapidly pigmenting melanocytic naevi as well as risks from product impurities and needle sharing (Langan et al., 2010). Long-term safety, carcinogenic potential and effect sizes remain uncharacterized; no conclusions on efficacy or safety can be drawn from the existing evidence.
Storage and handling
Lyophilized peptides are generally stored cool, dry and protected from light; for long-term storage, temperatures around -20 °C are commonly cited in the literature. After reconstitution, peptide solutions are typically kept refrigerated (2-8 °C) and used within a few days, as stability in solution is limited. Repeated freeze-thaw cycles are considered unfavorable.
Questions about the research
- What has Melanotan II been investigated for in research?
- Melanotan II was originally developed in the 1990s as an investigational pigmentation agent: a pilot phase I study examined tanning responses after subcutaneous administration. A small placebo-controlled study additionally investigated pro-erectile effects in men with erectile dysfunction. Current research mainly uses the substance as a pharmacological tool to probe the melanocortin receptors MC1R, MC3R and MC4R.
- What is the state of the evidence on Melanotan II?
- Only small early-phase clinical studies exist; development was discontinued and no phase 2 or phase 3 program was ever completed. Melanotan II is not approved as a medicine in any country, and the dermatological literature describes adverse events associated with unlicensed material. No conclusions on efficacy or safety can be drawn from this evidence base.
Sources
- Dorr et al., Life Sciences 1996DOI: 10.1016/0024-3205(96)00160-9PMID: 8637402
- Wessells et al., Urology 2000DOI: 10.1016/s0090-4295(00)00680-4PMID: 11018622
- Hadley & Dorr, Peptides 2006DOI: 10.1016/j.peptides.2005.01.029PMID: 16412534
- Langan et al., British Journal of Dermatology 2010DOI: 10.1111/j.1365-2133.2010.09891.xPMID: 20545686